“We believe tegoprubart has best-in-class potential as a novel immunosuppressive treatment option to prevent transplant rejection, with promising clinical results across kidney, xenograft, and now islet transplantations,” said David-Alexandre C. Gros, Chief Executive Officer of Eledon. “Recent encouraging data from the UChicago Medicine trial in type 1 diabetes, combined with our accelerated enrollment in the Phase 2 BESTOW trial and our strong capital position following our recent oversubscribed financing, has put us in a strong position to advance tegoprubart’s development. We look forward to sharing results from our BESTOW trial in the fourth quarter of 2025.”
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELDN:
- ELDN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Eledon Pharmaceuticals Announces $85 Million Stock Offering
- Eledon Pharmaceuticals Reports Promising Trial Results for Tegoprubart
- Eledon announces data for islet transplant recipients treated with tegoprubart
- Eledon Pharmaceuticals prices 18.36M shares at $3.65 in underwritten offering